Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 277 citing articles:

C-reactive protein levels in the early stage of COVID-19
L. Wang
Médecine et Maladies Infectieuses (2020) Vol. 50, Iss. 4, pp. 332-334
Open Access | Times Cited: 673
COVID-19: A promising cure for the global panic
Balachandar Vellingiri, Kaavya Jayaramayya, Mahalaxmi Iyer, et al.
The Science of The Total Environment (2020) Vol. 725, pp. 138277-138277
Open Access | Times Cited: 636
ACE2: The Major Cell Entry Receptor for SARS-CoV-2
Filippo Scialò, Aurora Daniele, Felice Amato, et al.
Lung (2020) Vol. 198, Iss. 6, pp. 867-877
Open Access | Times Cited: 439
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19
Joydeb Majumder, Tamara Minko
The AAPS Journal (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 439
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
James Brett Case, Paul W. Rothlauf, Rita E. Chen, et al.
Cell Host & Microbe (2020) Vol. 28, Iss. 3, pp. 475-485.e5
Open Access | Times Cited: 436
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju, Qi Zhang, Xiangyang Ge, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 381
Immune-mediated approaches against COVID-19
Helena F. Florindo, Ron Kleiner, Daniella Vaskovich‐Koubi, et al.
Nature Nanotechnology (2020) Vol. 15, Iss. 8, pp. 630-645
Open Access | Times Cited: 337
Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade
Luca Perico, Ariela Benigni, Giuseppe Remuzzi
˜The œNephron journals/Nephron journals (2020) Vol. 144, Iss. 5, pp. 213-221
Open Access | Times Cited: 315
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2
Shibi Muralidar, Senthil Visaga Ambi, Saravanan Sekaran, et al.
Biochimie (2020) Vol. 179, pp. 85-100
Open Access | Times Cited: 310
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andréani, Marion Le Bideau, Isabelle Duflot, et al.
Microbial Pathogenesis (2020) Vol. 145, pp. 104228-104228
Open Access | Times Cited: 305
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Arun K. Ghosh, Margherita Brindisi, Dana Shahabi, et al.
ChemMedChem (2020) Vol. 15, Iss. 11, pp. 907-932
Open Access | Times Cited: 296
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Guangyu Zhou, Qi Zhao
International Journal of Biological Sciences (2020) Vol. 16, Iss. 10, pp. 1718-1723
Open Access | Times Cited: 274
Updated Approaches against SARS-CoV-2
Hai-Ou Li, Yunjiao Zhou, Meng Zhang, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 64, Iss. 6
Open Access | Times Cited: 271
Current pharmacological treatments for COVID‐19: What's next?
Cristina Scavone, Simona Brusco, Michele Bertini, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4813-4824
Open Access | Times Cited: 270
Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins
Suhas Srinivasan, Hongzhu Cui, Ziyang Gao, et al.
Viruses (2020) Vol. 12, Iss. 4, pp. 360-360
Open Access | Times Cited: 266
The 2019 novel coronavirus disease (COVID-19) pandemic
Pranab Chatterjee, Nazia Nagi, Anup Agarwal, et al.
The Indian Journal of Medical Research (2020) Vol. 151, Iss. 2-3, pp. 147-159
Open Access | Times Cited: 259
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
Kushal Suryamohan, Devan Diwanji, Eric Stawiski, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 211
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Farhad Seif, Hossein Aazami, Majid Khoshmirsafa, et al.
International Archives of Allergy and Immunology (2020) Vol. 181, Iss. 6, pp. 467-475
Open Access | Times Cited: 195
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Dharma Rao Tompa, Aruldoss Immanuel, Srimari Srikanth, et al.
International Journal of Biological Macromolecules (2021) Vol. 172, pp. 524-541
Open Access | Times Cited: 190
A hypothesis for pathobiology and treatment of COVID‐19: The centrality of ACE1/ACE2 imbalance
Krishna Sriram, Paul A. Insel
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4825-4844
Open Access | Times Cited: 189
Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach
Syed Ovais Aftab, Muhammad Zubair Ghouri, Muhammad Masood, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 183
Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications
Nehla Banu, Sandeep Surendra Panikar, Lizbeth Riera Leal, et al.
Life Sciences (2020) Vol. 256, pp. 117905-117905
Open Access | Times Cited: 181
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity
Zhengnan Shen, Kiira Ratia, Laura Cooper, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2940-2955
Open Access | Times Cited: 177
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
Wei Zhu, Catherine Z. Chen, Kirill Gorshkov, et al.
SLAS DISCOVERY (2020) Vol. 25, Iss. 10, pp. 1141-1151
Open Access | Times Cited: 172
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor
A M Davidson, Jan Wysocki, Daniel Batlle
Hypertension (2020) Vol. 76, Iss. 5, pp. 1339-1349
Open Access | Times Cited: 169
Page 1 - Next Page

Scroll to top